| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/18/2001 | US6291500 Administering an antifungal agent |
| 09/18/2001 | US6291479 Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases |
| 09/18/2001 | US6291471 Use of apomorphine for the treatment of organic erectile dysfunction in males |
| 09/18/2001 | US6291462 Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates |
| 09/18/2001 | US6291445 For the treatment of conditions of the nose. |
| 09/18/2001 | US6291436 Anti-mycotic materials are commonly added to perishable foods susceptible to mold, yeast, or fungal growth to inhibit the growth of such materials in the food and extend the shelf-life of the foods. |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | US6291013 Mixing solution of excipient dissolved in first solvent with second solvent partially soluble in first solvent to form emulsion, adding extraction phase comprising third solvent which is nonsolvent for excipient, evaporating solvent |
| 09/18/2001 | US6290996 Administering an extract blend of the fruit of the emblica officinalis plant |
| 09/18/2001 | US6290994 Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity |
| 09/18/2001 | US6290991 Solid dose delivery vehicle and methods of making same |
| 09/18/2001 | US6290990 Slow-release matrix pellets and the production thereof |
| 09/18/2001 | US6290989 Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract |
| 09/18/2001 | US6290988 Encapsulated material with controlled release |
| 09/18/2001 | US6290987 Alkali metal alkyl sulfate, at least one membrane mimetic amphiphile, and at least one phospholipid. |
| 09/18/2001 | US6290985 By chewing the gum, the medicament or agent is released from the product. |
| 09/18/2001 | US6290984 Nonaqueous solvent and at least one non-water-soluble alkyl cellulose or hydroxyalkyl cellulose. |
| 09/18/2001 | US6290983 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
| 09/18/2001 | US6290982 Polycaprolactone and/or lactide; biodegradable polymeric material which melts within a certain narrow temperature range and which is either a mechanically tough plastic, a wax or a rubbery material |
| 09/18/2001 | US6290974 Complex comprising beta-lactoglobulin (purified by bioselective absorption to an immobilized affinity ligand) and vitamin a, vitamin d, vitamin e, vitamin k1, cholesterol, or conjugated linoleic acid; food additive |
| 09/18/2001 | US6290970 Transferrin receptor protein of Moraxella |
| 09/18/2001 | US6290967 Stabilizers for lyophilized vaccines |
| 09/18/2001 | US6290960 Vaccine and antitoxin for the treatment of C. difficile disease |
| 09/18/2001 | US6290952 Method of dephosphorylating an endotoxin in vivo with alkaline phosphatase |
| 09/18/2001 | US6290931 The spray drying process, since the evaporation of the solvent takes place within fractions of a second, is an extremely gentle process precisely for thermally vulnerable steroids (such as sulfamate steroids). |
| 09/18/2001 | US6290930 Cosolvent, especially ethanol, present in an amount that dissolves or solubilizes the budesonide in the mixture of cosolvent and propellant. |
| 09/18/2001 | US6289892 Partial liquid breathing of fluorocarbons |
| 09/18/2001 | CA2231118C Pharmaceutical preparation containing nimesulide for topical use |
| 09/18/2001 | CA2168364C Stabilized pharmaceutical composition containing bupropion |
| 09/18/2001 | CA2139133C Solid and liquid solutions of drugs which ar not readily soluble in water |
| 09/14/2001 | CA2340601A1 Roll-on applicator containing a capillary composition |
| 09/13/2001 | WO2001066700A1 Transcutaneous immunization for large particulate antigens |
| 09/13/2001 | WO2001066697A2 Serum free cultivation of primate embryonic stem cells |
| 09/13/2001 | WO2001066684A1 Method for producing moulded bodies |
| 09/13/2001 | WO2001066498A2 Method for obtaining a purified hydrofluoroalkane, purified hydrofluoroalkane, use of same and method for analysing same |
| 09/13/2001 | WO2001066241A1 Microcapsules - vi |
| 09/13/2001 | WO2001066240A1 Skincare agents |
| 09/13/2001 | WO2001066214A1 Methods for extraction and reaction using supercritical fluids |
| 09/13/2001 | WO2001066159A1 Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such |
| 09/13/2001 | WO2001066151A1 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 09/13/2001 | WO2001066145A1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 09/13/2001 | WO2001066137A1 Adenovirus formulations |
| 09/13/2001 | WO2001066123A2 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | WO2001066121A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 09/13/2001 | WO2001066115A2 Acetylsalicylic acid solutions |
| 09/13/2001 | WO2001066109A1 Oral pharmaceutical compositions containing n-sulphonylindoline derivatives |
| 09/13/2001 | WO2001066104A2 Retinoid formulations for aerosolization and inhalation |
| 09/13/2001 | WO2001066095A1 Stretchable patch |
| 09/13/2001 | WO2001066094A1 Controlled release oral solid forms containing mesalazine as active agent |
| 09/13/2001 | WO2001066093A2 Sustained release ranolazine formulations |
| 09/13/2001 | WO2001066091A1 Method of preparing solid dispersions |
| 09/13/2001 | WO2001066090A1 Micronized pharmaceuticals |
| 09/13/2001 | WO2001066089A2 Pharmaceutical compositions comprising cannabis |
| 09/13/2001 | WO2001066088A1 New self emulsifying drug delivery system |
| 09/13/2001 | WO2001066087A1 New self emulsifying drug delivery system |
| 09/13/2001 | WO2001066086A1 Lipid carrier |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001066084A2 Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
| 09/13/2001 | WO2001066083A1 Gel preparations for oral administration having improved preservation properties |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 09/13/2001 | WO2001066053A1 Colored visco-elastic composition |
| 09/13/2001 | WO2001065936A1 Method for immune switching |
| 09/13/2001 | WO2001065911A2 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | WO2001028492A3 Polyanhydrides with biologically active degradation products |
| 09/13/2001 | WO2001026635A3 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 09/13/2001 | WO2001017536A3 Novel autogenous vaccines used to obtain an immune tolerance |
| 09/13/2001 | WO2001015734A3 High viscosity liquid controlled delivery system and medical or surgical device |
| 09/13/2001 | WO2001015671A3 Flushable disposable polymeric products |
| 09/13/2001 | WO2001013906A3 Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| 09/13/2001 | WO2001009000B1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 09/13/2001 | WO2001003744A3 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of the c, d or v genes |
| 09/13/2001 | WO2000044681A9 Method for preparing porous shells or gels from glass particles |
| 09/13/2001 | WO2000041731A9 Reverse gene therapy |
| 09/13/2001 | WO1997042968A3 Administration of histamine for therapeutic purposes |
| 09/13/2001 | US20010021822 Osmotic delivery system with membrane plug retention mechanism |
| 09/13/2001 | US20010021758 Drugs, medical diagnosis |
| 09/13/2001 | US20010021723 Histochrome and its therapeutic use in ophthalmology |
| 09/13/2001 | US20010021722 Pharmaceutical compositions comprising monoamine oxidase b inhibitors |
| 09/13/2001 | US20010021721 Storage stability |
| 09/13/2001 | US20010021703 Crosslinking the micelle components to completely entrap the drug until it is delivered to the site of action; nondiffusing |
| 09/13/2001 | US20010021694 Treating bulimia and eating disorders, stimulating cholecystokinin, protein powder with glycomacropeptide or casein, fatty acid, fiber |
| 09/13/2001 | US20010021693 Non-aqueous or oily injection formulation obtainable by in-situ preparation and stabilization of the free, unstable base of valnemulin; treating infectious diseases in livestock and domestic animals; storage stability |
| 09/13/2001 | US20010021403 Gastrointestinal disorders |
| 09/13/2001 | US20010021392 Such as ibuprofen |
| 09/13/2001 | US20010021390 Mixture containing cetylpyridium chloride |
| 09/13/2001 | US20010021389 Calcium phosphate microcarriers and microsphers |
| 09/13/2001 | US20010021385 Human papillomavirus vaccine with disassembled and reassembled virus-like particles |
| 09/13/2001 | US20010021384 Administering vaccine |
| 09/13/2001 | US20010021377 Drug delivery; medical equipment |
| 09/13/2001 | US20010021373 Coated chewing gum products containing an acid blocker |
| 09/13/2001 | DE10011081A1 Lacquer formulation for treating and preventing onychomycosis, comprising combination of systemic and topical antimycotic agents in film-forming polymer base |
| 09/13/2001 | DE10011032A1 Stable solutions of acetylsalicylic acid in mixture of organic solvent and water, useful for topical treatment of pain, especially pain associated with herpes zoster |
| 09/13/2001 | DE10010759A1 Production of actives-containing moldings (especially tablets for detergent, pharmaceutical, agricultural or adhesive use) by solidification in presence of reactive components to reduce amount of heat or pressure required |
| 09/13/2001 | DE10010509A1 Oral pharmaceutical formulations with controllable release characteristics, e.g. rapid or delayed release, contain sucrose fatty acid ester as drug release controlling agent |
| 09/13/2001 | DE10010264A1 Production of nano- or micro-capsules used in the production of liposomes coated with polyelectrolytes comprises electrically recharging template particles with polyelectrolytes |
| 09/13/2001 | DE10010194A1 Production of micro- and/or nano-capsules used e.g. for encapsulating pharmaceutical and cosmetic active ingredients comprises mixing together the starting materials under laminar conditions and encapsulating in the conventional manner |
| 09/13/2001 | DE10010113A1 Isolation of collagen by extraction from sponge, giving product having cyclooxygenase inhibiting activity, useful for treating inflammatory diseases such as arthritis or skin inflammation |
| 09/13/2001 | DE10008506A1 Verfahren zur Herstellung von pharmazeutischen Darreichungsformen Process for the preparation of pharmaceutical dosage forms |
| 09/13/2001 | CA2799545A1 Adenovirus formulations |
| 09/13/2001 | CA2402509A1 Methods and kits for locally administering an active agent to an interstitial space of a host |